Your position : Home > Faculty and Staff > Faculty Members > M ~ P

  • BIO
  • Research Projects
  • Publications
JingXuan Pan
JingXuan Pan

Professor of Medicine Deputy Director, State Key Laboratory of Ophthalmology Sun Yat-sen University Zhongshan Ophthalmic Center. The research of Dr. Jingxuan Pan's lab is in the areas of tumor pharmacology and ocular tumor. His major research interests are to validate novel molecular targets in tumor cells, with particular emphasis on ocular tumor cells, develop novel and specific therapeutic agents and elucidate the mechanisms of drug action.

54 South Xianlie Road, Guangzhou, China

Clinical and Basical Research:

Uveal melanoma is the most common intraocular tumor in adults. There is no targeted therapy available for patients with uveal melanoma. Dr. Pan's group sought to dissect the molecular mechanism of pathogenesis and develop molecularly-targeted therapeutic agents. They identified that neddylation inhibitor MLN4924 (Clin Cancer Res 2018), antihelminthic drug niclosamide (Theranostics), photosensitizer verteporfin (Am J Cancer Res 2016), and HDAC inhibitor JSL-1 (Cancer Lett 2017) are active against uveal melanoma.

In addition, resistance to the first generation tyrosine kinase inhibitor Gleevec is a challenge. Dr. Pan and his colleagues synthesized compounds including novel small molecule compounds GZD824 and S116836, and discovered the effect of the third-generation of tyrosine kinase inhibitors (e.g. ponatinib, DCC-2036) on Gleevec-resistant T674I PDGFRa and D816V KIT. Dr. Pan's group also discovered several compounds [e.g., triptolide, pristimerin and SNS-032 (transcription inhibitors), homoharringtonine (a translation inhibitor), and celastrol (an hsp90 inhibitor)] are effective against Gleevec-resistant tumor cells regardless of resistance to Gleevec. Recently, Dr. Pan's group validated several druggable targets such as PRMT5 (J Clin Invest 2016), NAE1 (Cancer Res 2018), EZH2 (Clin Cancer Res 2018) and AXL (Clin Cancer Res 2017) to fine-tune self-renewal and maintenance of cancer stem cells.

Dr. Pan has been the principal investigator for several research projects supported by grants from National Natural Science Funds for Distinguished Young Scholars, the Major Research Plan of the National Natural Science Fund of China, the National Basic Research Program of China, and the National High Technology Research and Development Program of China. Dr. Pan has authored over 70 articles published in international peer-reviewed journals including J Clin Invest, Nat Commun, Cancer Res, Clin Cancer Res, and Blood. He is Associate Editor in Mol Cancer, and Current Mol Medicine.

Email : panjx2@mail.sysu.edu.cn

Research Projects


Selected recent publications

  1. Jin Y, Zhang P, Wang Y, Jin B, Zhou J, Zhang J, Pan J (通讯作者). Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma. Clin Cancer Res. 2018;24(15):3741-3754. PMID: 29233905.

  2. Liu C, Nie D, Li J, Du X, Lu Y, Li Y, Zhou J, Jin Y*, and Pan J*. Antitumor effects of blocking protein neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells. Cancer Res. 2018; 78 (6) 1522-1536. PMID: 29321163.

  3. Zhou J, Nie D, Li J, Du X, Lu Y, Li Y, Liu C, Dai W, Wang Y, Jin Y, Pan J*.  PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia. Clin Cancer Res. 2018;24(1):145-157. PMID: 29070525.

  4. Zhou J, Jin B, Jin Y, Liu Y,  Pan J*. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics. 2017; 7(6):1447-1462. PMID: 28529629.

  5. Jin Y, Nie D, Li J, Du X, Lu H, Li Y, Liu C, Zhou J, Pan J*. Gas6/AXL signaling regulates self-renewal of chronic myelogenous leukemia stem cells by stabilizing β-catenin. Clin Cancer Res. 2017; 23(11):2842-2855. Issue Highlights (June 1, 2017). PMID: 27852702.

  6. Jin B, Wang C, Li J, Du X, Ding K,  Pan J*. Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1/β-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia. Clin Cancer Res. 2017; 23(3):789-803. PMID: 27492973.

  7. Wang Y, Liu M, Jin Y, Jiang S,  Pan J*. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. Cancer Lett. 2017; 400:47-60. PMID: 28455241.

  8. Zheng L, Liu Y, Pan J*. The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells. Current Cancer Drug Targets. 2018;18(10):988-99. PMID: 29692251.

  9. Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R,  Pan J*. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 2016;126(10):3961-3980. PMID: 27643437. 

  10. Ma Y, Liu Y and  Pan J*. The photosensitizer verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. Am J Cancer Res. 2016; 6(12):2816-2830.

  11. Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, Yeung SC, Pan J*. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and Bcr-Abl oncogene addiction in malignant hematologic cells. Clin Cancer Res. 2012; 18(7):1966-1978. PMID: 22447844.

  12. Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, Liang Y, Zhang R, Pan J, Zeng YX, Kang T. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest. 2012; 122(6):2165-75. PMID: 22585575.

  13. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J*. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kB pathway and generation of reactive oxygen species. Cancer Res. 2010; 70(6): 2516–27. PMID: 20215516. 

  14. Xu F, Shi X, Li S, Cui J, Lu Z, Jin Y, Lin Y,  Pang J and Pan J*. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. Bioorg Med Chem. 2010; 18:1806–1815. PMID: 20149665. 

  15. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J*. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009; 15(5):1686-1697. PMID: 19240172.